Glaucoma

Evaluating images for quality, artifacts, and segmentation errors.

With this new funding, Smartlens gives the possibility of new treatment for glaucoma with miLens.

The financing will help advance the company’s novel treatment system for glaucoma and other chronic ophthalmic diseases.

Procedures in the pipeline hold greater appeal for cataract and refractive surgeons, patients.

The Laroche Glaucoma Risk Calculator is a valuable tool for glaucoma screenings both in the community and in optometrist offices.

The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego where he shared insights from his presentation comparing patient results of the Hydrus stent and the iStent inject W with or without ABiC (or ab-interno canaloplasty).

Diagnostic test results may vary in the same patient on the same day.

The iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has a PDUFA date of December 22, 2023.

In this recent study, Bharti Nihalani-Gangwani, MD, and Deborah VanderVeen, MD, reported that 29% developed glaucoma in a large infant cohort and the risk factors at the American Society of Cataract and Refractive Surgery annual meeting in San Diego.

Jason Bacharach, MD, presented results at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, highlighting that a large phase 3 clinical trial demonstrated no relevant differences between the 2 formulations.

Eyecelerator kicks off today as the American Society of Cataract and Refractive Surgery will host this year’s ASCRS and ASOA Annual Meeting in San Diego, California, beginning on Friday. ViaLase Inc., Aurion Biotech among companies presenting at the annual meeting.

The medical technology company ViaLase will reveal the 2-year data from their FLigHT clinical study as well as give additional information about their pipeline at ASCRS 2023.

I. Paul Singh, MD, gives a brief overview of the glaucoma panel discussion during the 2023 Controversies in Modern Eye Care meeting.

Alena Reznik, MD, shares short reflections on the glaucoma panel presented during the 2023 Controversies in Modern Eye Care meeting.

Danica J. Marrelli, OD, FAAO, shares highlights from the glaucoma panel, which she was part of during the 17th annual Controversies in Modern Eye Care meeting.

The study found that pseudophakic children older at the time of surgery developed a glaucoma-related adverse event less frequently.

Pediatric glaucoma, although rare, can cause irreversible vision loss and leave children visually impaired if not treated timely and adequately.

Physicians should continue to have conversations and assessments of patients with glaucoma before the decision is reached to stop driving.

A look back on what happened in optometry during the week of March 10-March 16.

Empowering individuals to take greater ownership of their visual health.

Nate Lighthizer, OD, gives highlights from his SECO 2023 presentation, "The glaucoma compass."

This recall is being initiated out of an abundance of caution due to cracks that have developed in some of the units caps of brimonidine tartrate ophthalmic solution bottles

Supplementing vision care with nutrition may protect ocular tissues.

A look back on what's happened in optometry during the week of February 11-February 16.

Patrick Mooney, CEO of SpyGlass Pharma, sits down to discuss the 6-month first-in-human clinical trial data of their drug delivery platform with bimatoprost, which is implanted during routine cataract surgery.

Medical and surgical technological advances show promise for future glaucoma management.

A look back on what's happened in optometry during the week of February 4-February 9.

Danica Marrelli, OD, FAAO, shares key highlights from her presentation, which she presented during the Glaucoma 360 meeting held this year in San Francisco.

According to the Ocular Hypertension Treatment Study, 5 risk factors are associated with high or low risk for primary open-angle glaucoma (POAG), with the intraocular pressure (IOP) historically being the “gold standard” and only modifiable risk factor.